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ABSTRACT 
 
We carried out an siRNA screen to identify targets for cutaneous squamous cell carcinoma 
(cSCC) therapy in the ubiquitin/ubiquitin-like (UBL) system.  We provide evidence for 
selective anti-cSCC activity of knockdown of the E3 ubiquitin ligase MARCH4, the ATPase 
p97/VCP, the deubiquitinating enzyme USP8, the cullin-RING ligase (CRL) 4 substrate 
receptor CDT2/DTL and components of the anaphase promoting complex/cyclosome 
(APC/C).  Specifically attenuating CRL4CDT2 by CDT2 knockdown can be more potent in 
killing cSCC cells than targeting CRLs or CRL4s in general by RBX1 or DDB1 depletion.  
Suppression of APC/C or forced APC/C activation by targeting its repressor EMI1 are both 
potential therapeutic approaches.  We observed that cSCC cells can be selectively killed by 
small-molecule inhibitors of USP8 (DUBs-IN-3/compound 22c) and the NEDD8 E1 
activating enzyme/CRLs (MLN4924/pevonedistat).  A substantial proportion of cSCC cell 
lines are very highly MLN4924-sensitive.  Pathways that respond to defects in proteostasis 
are involved in the anti-cSCC activity of p97 suppression.  Targeting USP8 can reduce the 
expression of growth factor receptors that participate in cSCC development.  EMI1 and CDT2 
depletion can selectively cause DNA re-replication and DNA damage in cSCC cells.   
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INTRODUCTION 
There is need for improved treatment for cSCC in high-risk recessive dystrophic 
epidermolysis bullosa (RDEB) and immunocompromised patients, including transplant 
recipients and in the general population (Harwood et al., 2016, Mellerio et al., 2016).  This 
includes better systemically and locally-delivered therapy.  The cumulative risk of death from 
cSCC in RDEB patients is 80% by the age of 55 and overall cSCC causes 25% of skin cancer-
related deaths.  cSCC, including multiple primary tumours in high-risk individuals, also 
results in considerable morbidity.   
The ubiquitin/UBL system plays a widespread role in regulating cellular pathways and 
processes.  It contains multiple classes of proteins including: E1 activating enzymes, E2 
conjugating enzymes, E3 ligases, ubiquitin/UBL-binding proteins, ATPases and proteases.  
Considerable work has been carried out to target this system for cancer therapy and there are a 
growing number of small-molecule modulators.   
We have shown that proteasome and ubiquitin E1 inhibitors have therapeutic potential 
for cSCC (McHugh et al., 2018).  In this study we screened using an siRNA library 
complementary to over 1000 genes to identify additional components of the ubiquitin/UBL 
system that could be targeted for cSCC therapy.  We assessed the cSCC selectivity compared 
to normal skin cells of knockdown and small-molecule inhibition of targets identified in the 
screen.  We also initiated studies to investigate mechanisms of anti-cSCC activity.   
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RESULTS AND DISCUSSION 
 
siRNA Screening for Potential Therapeutic Targets 
A cell line derived from a primary RDEB cSCC (SCCRDEB4) was transfected with 
pools of 4 siRNA targeting 1,186 ubiquitin/UBL pathway-linked genes (MacKay et al., 2014).  
Cell viability was reduced by >65% by siRNA pools targeting 66 genes (Supplementary 
Figure S1).  Of these 6 encoded for ubiquitin system-related components of the spliceosome 
which we have investigated in detail (Hepburn et al., 2018).  To identify genuine targets we 
determined the effects on viability/death in SCCRDEB4 cells of 4 individual siRNAs.  
Variations in the responses to siRNAs could arise from differences in their effectiveness in 
knocking down the target and its splice variants as well as false negative or false positive off-
target effects.  At least 2 siRNAs reduced cell viability (live cell number) by >60% for 34 
genes and increased cell death to >30% for 22 genes (Figure 1).  Some of these genes encoded 
for proteins that are subunits of the same complexes others for proteins that participate in the 
same cellular processes.  For the majority of the remaining targets only a single siRNA had a 
robust effect on cell viability/death (Supplementary Figure S2).   
 
Additional Target Validation 
To further investigate the therapeutic potential of suppression of genes for which multiple 
individual siRNAs had a phenotype we determined the effects of the siRNAs on 
viability/death in normal skin cells (NHF and NHK) and cell lines derived from metastasis in 
an RDEB (SCCRDEBMet) and a transplant patient (SCCTMet).  A cytotoxic siRNA was 
used in each experiment as a control for transfection efficiency.  In addition, we determined 
the extent of target protein knockdown in normal and cSCC cells.  The effects of small-
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molecule inhibitors on viability/death in normal skin cells and cSCC cell lines were also 
evaluated.   
 
MARCH4 
MARCH4 is a little-studied transmembrane E3 ubiquitin ligase that is localised to the Golgi 
apparatus (Bartee et al., 2004, Bauer et al., 2017, Samji et al., 2014).  Ectopically expressed 
MARCH4 increases lysosomal degradation of several proteins that promote immune 
responses and its knockdown increases cell surface levels of the scaffolding protein 
tetraspanin CD81 (Bartee et al., 2010).  However, there are likely to be additional MARCH4 
substrates (Nathan and Lehner, 2009).   
MARCH4 siRNAs had little effect on death in normal skin cells while 2 MARCH4 
siRNAs caused a reduction in viability and increased death in cSCC cell lines (Figure 2a).  
We were unable to detect MARCH4 protein with available antibodies (data not shown).  
However, we confirmed that MARCH4 mRNA levels were reduced in NHK by MARCH4 
siRNAs and that in SCCRDEB4 cells the siRNAs most potent in killing cSCC cells caused 
the largest reduction in MARCH4 mRNA levels (Figure 2b).   
 
p97/VCP 
p97 is an ATPase which unfolds ubiquitinated proteins and extracts them from membranes, 
cellular structures and complexes (van den Boom and Meyer, 2018, Ye et al., 2017).  Through 
this p97 can facilitate substrate degradation by the proteasome and it can also regulate 
substrate activity, complex assembly and membrane fusion.  p97 participates in a wide range 
of cellular processes.  It maintains protein homeostasis (proteostasis) by promoting the 
proteasomal degradation of misfolded proteins associated with the endoplasmic reticulum, 
ribosomes and mitochondria.  It also regulates lysosomes and autophagosome maturation.  
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Other roles of p97 include the control of key proteins involved in signal transduction, DNA 
replication and DNA repair.  Distinct p97 complexes are involved in particular cellular 
processes: p97 associates with numerous adaptors and cofactors which recruit substrates and 
participate in substrate processing (Stach and Freemont, 2017, Ye et al., 2017).   
p97 siRNAs killed cSCC lines but not normal skin cells while p97 was depleted in both 
NHK and SCCRDEB4 cells (Figure 2c and d).  We investigated whether p97 knockdown-
induced death was dependent on pathways that sense defects in proteostasis.  Death due to 
depletion of p97 was attenuated by suppression of proteins involved in responses to the 
accumulation of unfolded proteins in the endoplasmic reticulum (ATF6, IRE1a/JNK, 
PKR/eiF2α) and to amino acid depletion (GCN2/eiF2α) (Figure 2e) (McConkey, 2017, 
Parzych et al., 2015).  cSCCs have frequent gene copy number changes and UV-induced 
cSCCs in particular have extremely high gene mutation rates (Cho et al., 2018, Inman et al., 
2018, South et al., 2014).  These alterations can confer greater dependency on mechanisms of 
proteostasis by causing imbalanced protein production which can generate free components of 
complexes that cannot fold appropriately and through the generation of proteins that are 
misfolded due to mutations (Deshaies, 2014, Vekaria et al., 2016).  Consistent with greater 
basal proteotoxic stress there is an increase in the expression of proteasome subunits and 
Ser51 phosphorylated eiF2ɑ in cSCC cell lines compared to normal skin cells (McHugh et al., 
2018).   
Numerous small-molecule p97 inhibitors have been developed (Chapman et al., 2015, 
Vekaria et al., 2016, Ye et al., 2017).  The well characterised p97 inhibitors DBeQ and NMS-
873 were at best modestly selective for effects on viability/death in cSCC lines compared to 
normal skin cells and the sensitivity of the most responsive cSCC lines was around average 
for tumour-derived cells (Supplementary Figure S3) (Magnaghi et al., 2013, Parzych et al., 
2015).  It is possible that the differences in the cSCC selectivity of these inhibitors and p97 
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knockdown are due to divergent effects on the spectrum of p97-regulated pathways.  For 
example, the effects of p97 knockdown could be influenced by competition of binding 
partners for residual p97.  The potency of p97 inhibitors can be differentially affected by p97-
interacting proteins potentially resulting in preferential effects of inhibitors on particular 
complexes (Gui et al., 2016).  It would be of interest to compare additional p97 inhibitors to 
determine if greater cSCC selectivity can be achieved.   
 
USP8 
Sorting of endocytosed activated cell surface receptors for lysosomal degradation or recycling 
to the plasma membrane is mediated by endosomal sorting complexes required for transport 
(ESCRT).  Ubiquitination of receptors promotes ESCRT-mediated lysosomal trafficking.  
USP8/UBPY-mediated deubiquitination of some ESCRT-associated receptors can facilitate 
their recycling and USP8 also regulates endocytic sorting by stabilising ESCRT-0 proteins 
HGS, STAM and STAM2 (D'Arcy et al., 2015, Niendorf et al., 2007, Wright et al., 2011).   
USP8 siRNAs reduced viability and increased death in cSCC lines but had little effect 
in normal skin cells (Figure 3a).  The anti-cSCC potency of these siRNAs reflected their 
ability to reduce USP8 protein levels (Figure 3b).  siRNA USP8(A) depleted USP8 to the 
greatest extent and this was associated with reduced expression of growth factor receptors 
MET, EGFR and ERBB2 along with HGS and STAM2.  siRNAs USP8(B) and (C) reduced 
expression of MET and STAM2.  This is consistent with a role of USP8 in protecting these 
proteins from degradation.   
Small-molecule USP8 inhibitors have been identified including DUBs-IN-
3/compound 22c (Colombo et al., 2010, D'Arcy et al., 2015).  DUBs-IN-3 killed cSCC lines 
at lower concentrations than normal skin cells (Figure 3e).  Reduced MET, EGFR and 
STAM2 expression was consistent with attenuation of USP8 at DUBs-IN-3 concentrations 
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that selectively increased death in cSCC cells (Figure 3d).  We observed that directly targeting 
MET, EGFR or ERBB2 was sufficient to impact on cSCC cell viability (Figure 3c).  MET 
and EGFR/ERBB2 signalling pathways can contribute to driving cSCC development and a 
subset of cSCCs respond to EGFR inhibitors (Cataisson et al., 2016, Harwood et al., 2016, 
Mellerio et al., 2016).  Suppression of USP8 could provide a means to simultaneously 
interfere with multiple therapeutically relevant receptors which could overcome resistance 
due to receptor redundancy or cross-talk.   
 
APC/C 
The APC/C is a multisubunit E3 ligase that coordinates transitions through the cell cycle by 
targeting key proteins for proteasomal degradation (Alfieri et al., 2017, Zhou et al., 2016).  
CDC20 and CDH1/FZR1 are coactivators that associate with the core APC/C complex at 
different stages of the cell cycle and recruit overlapping but distinct sets of substrates for 
ubiquitination.  APC/CCDC20 drives progression through mitosis (Kapanidou et al., 2017).  
APC/CCDC20 is inhibited by the spindle assembly checkpoint (SAC) until chromosomes are 
properly attached to spindle microtubules.  Following transition through the SAC APC/CCDC20 
promotes the degradation of securin and cyclin B allowing chromatid segregation and mitotic 
exit.  In late mitosis and G1 APC/CCDH1 participates in promoting licensing of DNA for 
replication by allowing the recruitment of the pre-replicative complex to replication origins 
(Hernandez-Carralero et al., 2018, Moreno and Gambus, 2015).  This involves APC/CCDH1-
mediated degradation of geminin which is an inhibitor of the key replication licensing factor 
CDT1 and suppression of cyclin A and B CDK complexes which inhibit replication licensing.  
The attenuation of cyclin/CDKs also contributes to APC/CCDH1-mediated blockade of cell 
cycle progression.  In late G1, S and G2 phase cells APC/CCDH1 activity is inhibited in part by 
E2F-dependent induction of the APC/C-binding protein EMI1.  This prevents further rounds 
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of DNA replication licensing and permits entry into S phase (Abbas and Dutta, 2017, Cappell 
et al., 2016, Reimann et al., 2001).  APC/CCDH1 thus participates in allowing licensing to 
occur only before the onset of DNA replication which contributes to ensuring that the genome 
is just duplicated once per cell cycle.   
siRNA pools targeting 10 of the 14 core subunits of the APC/C substantially reduced 
viability in our primary screen and multiple individual APC/C core subunit siRNAs killed 
SCCRDEB4 cells (Supplementary Figure S1 and Figure 4a).  There was little effect on 
viability/death of targeting core APC/C subunits in normal skin cells but effects on 
SCCRDEBMet and SCCTMet cells were also generally modest (Figure 4a).  Interfering with 
coactivators CDC20 and CDH1 provides a means to specifically suppress different APC/C 
functions.  Two of the CDC20 siRNAs selectively killed cSCC cell lines while they robustly 
reduced CDC20 protein expression in both normal skin cells and SCCRDEB4 cells (Figure 
4b).  siRNA CDC20(D) was the least effective in depleting CDC20 and had no effect on 
viability/death.  Three CDH1 siRNAs depleted CDH1 without causing a high level of death 
in cSCC cells (Figure 4a and c).  These data suggest that CDC20 rather than CDH1 has 
potential as a therapeutic target for cSCC.   
CDC20 is essential for mitosis but a high level of suppression is required to block cell 
cycle progression in normal cells and in many tumour cells (Baumgarten et al., 2009, 
Crawford et al., 2016, Jin et al., 2010, Kidokoro et al., 2008, Li et al., 2014, Li et al., 2007, 
Taniguchi et al., 2008, Wirth et al., 2004, Zhang et al., 2014).  The robust effects of targeting 
APC/C core subunits and CDC20 in SCCRDEB4 cells likely reflects sensitivity to partial 
suppression of APC/C.  A need to maintain elevated levels of CDC20 for survival may 
contribute to cell death induced by CDC20 depletion in SCCRDEB4 and SCCRDEBMet 
cells (Supplementary Figure S5).  Small-molecule antagonists of CDC20/CDH1 (TAME) 
and CDC20 (apcin) are at an early stage of development (Kapanidou et al., 2017, Sackton et 
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al., 2014, Wang et al., 2015, Zeng et al., 2010).  Anti-mitotic agents including compounds 
that interfere with microtubule dynamics and Aurora A and PLK-1 inhibitors act in part by 
attenuating APC/CCDC20 by activating the SAC (Olziersky and Labidi-Galy, 2017).  Previous 
studies indicate PLK-1 is a potential target for cSCC therapy (Watt et al., 2011).  Direct 
APC/CCDC20 suppression may be a better therapeutic approach than SAC activation because 
directly targeting APC/CCDC20 attenuates premature exit from mitosis (Huang et al., 2009).   
We also observed that siRNAs targeting the APC/C repressor EMI1 killed cSCC lines 
with no effect on death in normal skin cells (Figure 4a).  This included SCCRDEBMet and 
SCCTMet cells which were relatively resistant to suppression of APC/C.  The anti-cSCC 
potency of the siRNAs was consistent with the extent of EMI1 knockdown (Figure 4d).  We 
investigated the role of DNA-re-replication in EMI1 knockdown-dependent death.  EMI1 
depletion caused a greater increase in DNA re-replication (greater than G2/M DNA content) 
in cSCC cells than in NHF along with a tumour cell-selective increase in the DNA damage 
marker γH2AX (Figure 4d and e and Supplementary Figure S4a).  Furthermore, death 
induced by EMI1 depletion was dependent on the DNA replication licensing factor CDT1 
(Figure 4f).  This is in line with previous studies in other cell types showing that reduced 
viability following EMI1 suppression can be caused by APC/CCDH1-dependent DNA re-
replication leading to DNA damage (Machida and Dutta, 2007, Neelsen et al., 2013, Shimizu 
et al., 2013, Verschuren et al., 2007).   
High expression of replication licensing factors increases susceptibility to re-
replication (Benamar et al., 2016, Munoz et al., 2017, Vaziri et al., 2003).  Elevated 
expression of replicating licensing proteins including CDT1 compared to normal skin cells 
consequently provides a mechanism that could contribute to increased re-replication in cSCC 
cells on targeting components of the protective machinery including EMI1 (Supplementary 
Figure S5).  This is supported by the observation that depletion of CDT1 diminished EMI1 
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knockdown-induced death (Figure 4f).  EMI1 increases expression of the CDT1 repressor 
geminin by attenuating APC/CCDH1-mediated geminin degradation.  In normal cells geminin 
accumulates inactive CDT1 in preparation for the next round of replication licensing 
(Ballabeni et al., 2004, Ballabeni et al., 2013).  EMI1 protein expression was strongly 
upregulated in cSCC cell lines which could prime cSCC cells for re-replication by 
contributing to the accumulation of CDT1 (Supplementary Figure S5).  Consistent with this 
we observed that EMI1 and CDT1 protein expression was frequently co-upregulated in cSCC 
cell lines and EMI1 knockdown reduced both geminin and CDT1 protein levels 
(Supplementary Figure S5 and Figure 4d).   
 
CRL4CDT2 
CRLs are a very large family of multisubunit E3 ubiquitin ligases containing 1 of 8 cullin 
scaffolds (Bulatov and Ciulli, 2015, Jang et al., 2018).  CRL4s are composed of: cullin4(A/B), 
DDB1 adaptor, RBX1 E2-binding RING finger and one of many substrate-recruiting 
receptors (Hannah and Zhou, 2015).  RBX1 is a component of multiple CRLs, cullin4 and 
DDB1 are present in all CRL4s and the receptors determine substrate specificity and 
consequently the cellular roles of CRL4 complexes.  siRNAs targeting DDB1, RBX1 and the 
CRL4 substrate receptors DCAF1/VPRBP and CDT2/DTL reduced viability in cSCC cell 
lines but had only a modest effect in normal skin cells (Figure 5a).  This indicates targeting 
CRL4s in particular CRL4DCAF1 or CRL4CDT2 can have selective anti-cSCC activity.  In 
support of this, suppression of CRL4s protects against UV-induced skin cancer in mice 
(Hannah and Zhou, 2013).  CDT2 knockdown could cause more death in cSCC cells than 
targeting RBX1 or DDB1 (Figure 5a and b).  RBX1/DDB1 depletion may elicit pro-survival 
responses through attenuation of CRLs in addition to CRL4CDT2.  Like EMI1, CRL4CDT2 is 
involved in protecting against DNA re-replication (Abbas and Dutta, 2011, 2017, Moreno and 
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Gambus, 2015).  During S-phase and DNA repair CRL4CDT2 promotes the DNA replication-
coupled proteasomal degradation of PCNA-bound proteins involved in promoting replication 
licensing including: CDT1, SET8 and p21 (Havens and Walter, 2011, Hernandez-Carralero et 
al., 2018, Scrima et al., 2011).  CDT2 was efficiently knocked down in both NHF and cSCC 
cells (Figure 5c).  This resulted in the accumulation of the CRL4CDT2 substrates SET8 and p21 
but not CDT1.  Failure to accumulate CDT1 is consistent with previous observations in other 
cell types and can result from context-dependent CDT1 regulatory mechanisms (Benamar et 
al., 2016).  We observed that CDT2 depletion caused cSCC-selective DNA re-replication and 
DNA damage and that CDT2 knockdown-induced death in cSCC cells was SET8-dependent 
(Figure 5c, d and e and Supplementary Figure S4a).  This is consistent with a key role of re-
replication in the anti-tumour activity of CDT2 suppression (Benamar et al., 2016, Olivero et 
al., 2014).   
There are no direct small-molecule inhibitors of CDT2.  However, 
MLN4924/pevonedistat an inhibitor of the NEDD8-activating enzyme attenuates CRLs by 
blocking their NEDDylation (Abidi and Xirodimas, 2015).  DNA re-replication due at least in 
part to CRL4CDT2 suppression can make a substantial contribution to the anti-tumour activity 
of this inhibitor although interference with other pathways is also involved (Abbas and Dutta, 
2017, Benamar et al., 2016, Zhou et al., 2018).  In cSCC cells MLN4924 caused DNA re-
replication and altered expression of proteins involved in promoting replication licensing 
although the pattern of changes was different from that caused by CDT2 knockdown (Figures 
6a and 5c and Supplementary Figure S4b).  It also increased γH2AX, indicative of DNA 
damage.  Viability was reduced at low MLN4924 concentrations in SCCRDEB4, 
SCCRDEBMet, SCCT and SCCTMet cells treated continuously for 72 hours (Figure 6b).  
Comparison with the GDSC Database (Release 8.0) indicates these cSCC lines are in the very 
highly MLN4924/pevonedistat-sensitive subset of cancer-derived cells (Yang et al., 2013).  
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Death in SCCIC1, SCCT, SCCTMet and SCCT8 cells was more sensitive than in normal skin 
cells to continuous MLN4924 treatment.  In addition, SCCRDEB4, SCCT and SCCTMet 
cells were selectively killed by an 8 hour pulse of MLN4924 which mimics systemically-
delivered inhibitor pharmacokinetics (Swords et al., 2015).  Clonogenic assays confirmed 
these differences in sensitivity to a pulse of MLN4924 (Figure 6c).  At low concentrations 
MLN4924 promoted growth in SCCRDEB2 and SCCIC1 cells.  Enhanced cell growth has 
been observed previously but is unusual and requires additional investigation (McMillin et al., 
2012).  p21 expression was high in 3 of the cSCC lines most insensitive to a pulse of 
MLN4924 (SCCIC1, SCCRDEB2 and SCCRDEB3) and p21 knockdown enhanced 
MLN4924-induced cell death in SCCRDEB2 cells (Supplementary figures S5 and S6).  This 
is consistent with previous reports that p21 can be protective against MLN4924 (Blank et al., 
2013, Lin et al., 2010).  Elevated basal p21 may consequently be a marker for resistance of 
cSCC cells to MLN4924.  Wild-type p53 can protect against MLN4924 in part through p21 
induction, however p53 is mutated in all cSCC lines (Lin et al., 2010, Malhab et al., 2016).  
Given the particular efficacy of CDT2 knockdown in killing cSCC cells, the differences in 
modulation of CRL4CDT2 substrates observed with CDT2 depletion and MLN4924 and the 
effects of MLN4924 on multiple pathways it would be of interest to develop CDT2-specific 
inhibitors.   
 
MATERIALS AND METHODS 
 
Cell culture  
Cells were maintained and plated as previously (McHugh et al., 2018).  SCCRDEBMet 
(SCCRDEB70) and RDEBK cells were provided by Dr Andrew P. South (Thomas Jefferson 
University), Jemima E. Mellerio (King's College London) and Julio C. Salas-Alanís (DEBRA 
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Mexico).  SCCT (previously published as MET1) and SCCTMet (previously published as 
MET4) and SCCIC1 and SCCIC1Met cell lines are derived from paired primary tumours and 
metastases (Hassan et al., 2019, Proby et al., 2000, Watt et al., 2011).   
 
siRNA transfection  
Dharmacon ON-TARGETplus modified siRNAs (Thermo Fisher Scientific, Waltham, MA, 
USA) were used in this study to minimise off-target effects.  Reverse transfection with 
synthetic siRNA duplexes (10 nM) was performed using Invitrogen Lipofectamine 
RNAiMAX (Thermo Fisher Scientific).  The library used for the primary screen containing 
pools of 4 siRNA per gene was detailed previously (MacKay et al., 2014).  Additional 
siRNAs are listed in Supplementary Figure S7a.   
 
Inhibitor treatment 
Inhibitors used in this work were DBeQ and NMS-873 (Selleckchem, Houston, TX, USA), 
DUBs-IN-3/compound 22c (Medchemexpress, South Brunswick Township, NJ, USA) and 
MLN4924 (Boston Biochem, Cambridge, MA, USA).   
 
Cell viability assays 
For the primary screen viability was measured by ATPase assay 96 hours after siRNA 
transfection (MacKay et al., 2014).  Where indicated, live cell number and cell death were 
analysed 96 hours after siRNA transfection or 72 hours after the initiation of inhibitor 
treatment using an Incucyte ZOOM real-time imager (Essen BioScience Ltd, Welwyn Garden 
City, UK) and the CellTox Green Cytotoxicity Assay (Promega, Southampton, UK).  For 
clonogenic assays MLN4924 was added for 8 hours and cells were maintained in drug-free 
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medium for up to 2 weeks.  Colonies were fixed in 10% methanol, 10% acetic acid and 
stained with crystal violet.   
 
DNA re-replication 
To assess re-replication (>G2/M DNA content) fixed DAPI stained samples were analysed for 
DNA content using a NucleoCounter NC-3000 cell counter (ChemoMetec, Allerod, 
Denmark) according to the manufacturer’s instructions.   
 
Western blotting 
Primary antibodies are listed in Supplementary Figure S7b.  Cell extracts were made by lysis 
into SDS electrophoresis sample buffer.  Western blotting was carried out as previously 
(Dayal et al., 2009).   
 
Real-Time PCR 
RNA was extracted using RNeasy columns and real-time PCR were performed as previously 
(Dayal et al., 2009) using MARCH4 probe/primer set Hs00863129_m1 (Thermo Fisher 
Scientific).  TBP was used for normalisation.   
 
Data availability statement 
The authors confirm that the data supporting the findings of this study are available within the 
article and its Supplementary Materials.   
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FIGURE LEGENDS 
 
Figure 1.  Targets in the ubiquitin/UBL system for which at least 2 siRNAs substantially 
reduced viability.  SCCRDEB4 cells were mock transfected (-) or transfected with non-
targeting siRNA (Control), cytotoxic siRNA (Tox) or 4 individual siRNAs for each target.  
Cell viability (percentage of control live cell number) and the percentage of dead cells were 
determined by real-time imaging 96 hours after transfection.  Values are the mean -/+ range of 
2 experiments or -/+ the SD of at least 3 experiments.  The cellular roles of targets are 
indicated.   
 
Figure 2.  MARCH4 and p97 knockdown selectively kills cSCC cells.  Normal skin cells 
(NHF, NHK) and cSCC lines (SCCRDEB4, SCCRDEBMet and SCCTMet) were mock 
transfected (-) or transfected with siRNAs as indicated.  Cell viability and the percentage of 
dead cells were determined by real-time imaging following transfection with 4 siRNAs 
targeting (a) MARCH4 or (c) p97: mean -/+ SD of at least 3 experiments (NHK, NHF and 
SCCRDEB4 cells) or -/+ the range of 2 experiments (SCCRDEBMet and SCCTMet cells).  
(b) MARCH4 mRNA knockdown: mean -/+ range of 2 experiments.  (d) p97 protein 
knockdown.  (e) Co-transfection of control or p97(D) siRNAs with siRNAs targeting genes 
involved in responding to defects in proteostasis (2 siRNAs per target): mean percentage of 
cell death in p97(D) and control siRNA transfected cells -/+ SD of 4 experiments.   
 
Figure 3.  Suppression of USP8 has selective anti-cSCC activity.  (a) Cell viability and the 
percentage of dead cells were determined by real-time imaging 96 hours after transfection 
with USP8 siRNAs: mean -/+ SD of at least 3 experiments (NHK, NHF and SCCRDEB4 
cells) or -/+ the range of 2 experiments (SCCRDEBMet and SCCTMet cells).  (b) Protein 
expression was analysed by western blotting 48 hours after transfection with USP8 siRNAs.  
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(c) Cell viability and the percentage of dead cells 96 hours after transfection with 2 siRNAs 
targeting growth factor receptors: mean -/+ SD of 4 experiments (d) Western blot analysis of 
SCCRDEB4 cells treated with the USP8 inhibitor DUBs-IN-3 for 24 hours.  (e) Cell viability 
and the percentage of dead cells 72 hours after initiation of DUBs-IN-3 treatment: mean -/+ 
range of 2 experiments.   
 
Figure 4.  APC/C suppression and derepression have potential for cSCC therapy.  (a) 
Cells were transfected with 4 siRNAs per target.  Cell viability and the percentage of dead 
cells were assessed 96 hours after transfection by real-time imaging: mean -/+ SD of at least 3 
experiments (CDC20, CDH1, and EMI1 in NHK, NHF and SCCRDEB4 cells) or -/+ range of 
2 experiments.  Protein expression analysed 48 hours after transfection with siRNAs 
targeting: (b) CDC20, (c) CDH1 and (d) EMI1.  Geminin (upper band *) and CDT1 
expression was reduced by EMI1 knockdown.  (e) The percentage of cells in which DNA was 
re-replicated 72 hours after siRNA transfection: mean -/+ range of 2 experiments.  (f) Cell 
death 72 hours after siRNA co-transfection: mean percentage of that in EMI1(C) and control 
siRNA transfected cells: mean -/+ SD of 3 experiments.   
 
Figure 5.  CRL4CDT2 is a potential therapeutic target for cSCC.  (a) Cells were transfected 
with 4 siRNAs targeting the CRL4 adaptor DDB1 and substrate receptors DCAF1 and CDT2 
and the CRL/CRL4 RING finger protein RBX1.  Viability and the percentage of dead cells 
were assessed by real-time imaging after 96 hours: mean -/+ range of 2 experiments.  Protein 
expression was analysed after 48 hours with 4 siRNAs targeting: (b) DDB1, RBX1, DCAF1 
and CDT2 in SCCRDEB4 cells and (c) CDT2 in NHF and SCCRDEB4 cells.  (d) The 
percentage of cells in which DNA was re-replicated 72 hours after siRNA transfection: mean 
-/+ range of 2 experiments.  (e) Viability/death were assessed by real-time imaging 96 hours 
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after siRNA co-transfection: mean percentage of cell death in CDT2(B) and control siRNA 
transfected cells: mean -/+ SD of 3 experiments.   
 
Figure 6.  A subset of cSCC lines are more sensitive than normal skin cells to death 
induced by MLN4924.  (a) SCCRDEB4 cells were incubated with the NEDD8 E1 activating 
enzyme/CRL inhibitor MLN4924 for 8 and 24 hours.  Protein expression was analysed by 
western blotting.  (b) Normal skin cells (NHF, NHK, RDEBK) or cSCC lines were 
continuously incubated with MLN4924 for 72 hours (Continuous) or treated with MLN4924 
for 8 hours and then maintained in drug-free medium for a further 64 hours (Pulse).  Cell 
viability and death were assessed by real-time imaging: mean -/+ SD of 3 experiments.  (c) 
Cells were incubated with the indicted concentration of MLN4924 (µM) for 8 hours 
(comparable to the pulse) and then maintained in drug-free medium to allow colony 
formation.   
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S1.  Sixty-six siRNA pools in the ubiquitin/UBL library 
reduced viability by more than 65%.  SCCRDEB4 cells were transfected with a 
pool of 4 non-targeting siRNAs (Control) or pools of 4 siRNAs complementary to 
1,186 ubiquitin/UBL system-related genes.  Cell viability was determined 96 hours 
after transfection by ATPase assay.  The average Z-prime for the screen was 0.82.  
Values are the mean percentage of control -/+ SD of 3 determinations.  The effects of 
4 individual siRNAs are indicated (Pool deconvolution). 
 
Supplementary Figure S2.  Targets from the primary screen for which multiple 
siRNAs did not cause a substantial reduction in viability.  SCCRDEB4 cells were 
transfected with 4 individual siRNAs per target gene and cell viability (percentage of 
control live cell number) and the percentage of dead cells were assayed by real-time 
imaging.  Values are the mean -/+ range of 2 determinations. For many of these 
targets one siRNA had a substantial effect on viability.  While it remains possible this 
is due to greater efficacy of target knockdown by the siRNA with the strongest 
phenotype it could also result from off-target effects.   
 
Supplementary Figure S3.  The p97 inhibitors DBeQ and NMS-873 do not 
display a high level of selectivity for cSCC cells.  Normal skin cells (NHF and 
NHK) and cSCC cell lines derived from RDEB (SCCRDEB), immunocompetent 
(SCCIC) and immunocompromised transplant (SCCT) patients were treated for 72 
hours with p97 inhibitors.  Cell viability (percentage of control live cell number) and 
the percentage of dead cells were assayed by real-time imaging.   
 
Supplementary Figure S4a.  EMI1 and CDT2 knockdown cause DNA re-
replication in cSCC cells.  The DNA content of NHF and SCCRDEB4 cells was 
analysed 72 hours after transfection with the indicated siRNA.  The percentage of 
cells that underwent re-replication (>G2/M DNA content) is shown.   
 
Supplementary Figure S4b.  MLN4924 promotes DNA re-replication in cSCC 
cells.  The DNA content of NHF and SCCRDEB4 cells was analysed 48 hours after 
treatment with carrier (0) or 1µM MLN4924.  The percentage of cells with >G2/M 
DNA content is indicated.   
 
Supplementary Figure S5.  The APC/C coactivators CDH1 and CDC20, the 
APC/C repressor EMI1 and proteins that promote DNA replication licensing are 
frequently upregulated in cSCC lines.  Protein expression was analysed by western 
blotting in normal skin cells (NHF, NHK, RDEBK) and a panel of lines derived from 
primary and metastatic cSCCs in RDEB (SCCRDEB), immunocompetent (SCCIC) 
and transplant patients (SCCT).  NHF1 and 2 and NHK1 and 2 were from different 
donors.   
 
Supplementary Figure S6.  p21 knockdown partially overcomes resistance to 
MLN4924.  SCCRDEB2 cells that are relatively insensitive to MLN4924 were 
transfected with p21 siRNAs.  (a) p21 protein knockdown assessed by western 
blotting 48 hours after transfection.  (b) 48 hours after transfection SCCRDEB2 cells 
were exposed to an 8 hour pulse of MLN4924.  Cell death was determined by real-
time imaging 72 hours after initiating treatment with the inhibitor.  p21 knockdown 
increased the level of cell death caused by an 8 hour pulse of MLN4924.   
Supplementary Figure S7.  Materials used in this study.  (a) siRNAs.  (b) Primary 
antibodies. 
